Mission statement · Company scope
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”
In use2026 – now1 sighting
First seenMar 2026Added
Last seenMar 2026Latest observation
Date created—Not published by the organization
Record
- Kind
- Mission
- Scope
- Company
- Style
- Impact (primary) · Innovation · Product offering
- Leads with
- Change
- Best for
- Mission-driven · Climate & health
- Formula
- A world where [change]
- Tone
- Aspirational · Technical
- Length
- 61 words · reading grade 19.1
- Review status
- unreviewed · classifier rules-v0
- Quality score
- 0.40
- Record
- st_b992e472ae6e96ec
- Classification confidence
- 0.71
Sources1 sighting
SEC
SEC EDGAR filingsObserved 2026-03-12 · sec_sentence · 10-K · accession 0001437749-26-007962
View filing ↗0 to compareCompare